Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GUTS logo GUTS
Upturn stock ratingUpturn stock rating
GUTS logo

Fractyl Health, Inc. Common Stock (GUTS)

Upturn stock ratingUpturn stock rating
$0.99
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: GUTS (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.67

1 Year Target Price $6.67

Analysts Price Target For last 52 week
$6.67 Target price
52w Low $0.82
Current$0.99
52w High $3.67

Analysis of Past Performance

Type Stock
Historic Profit 6.75%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 70.20M USD
Price to earnings Ratio -
1Y Target Price 6.67
Price to earnings Ratio -
1Y Target Price 6.67
Volume (30-day avg) 4
Beta -
52 Weeks Range 0.82 - 3.67
Updated Date 08/28/2025
52 Weeks Range 0.82 - 3.67
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.1

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.43
Actual -0.545

Profitability

Profit Margin -
Operating Margin (TTM) -587305.86%

Management Effectiveness

Return on Assets (TTM) -59.87%
Return on Equity (TTM) -379.75%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 109627935
Price to Sales(TTM) 4129.47
Enterprise Value 109627935
Price to Sales(TTM) 4129.47
Enterprise Value to Revenue 6448.7
Enterprise Value to EBITDA -
Shares Outstanding 70881400
Shares Floating 27939068
Shares Outstanding 70881400
Shares Floating 27939068
Percent Insiders 3.34
Percent Institutions 53.76

ai summary icon Upturn AI SWOT

Fractyl Health, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Fractyl Health is a medical technology company dedicated to developing novel, less invasive therapies for metabolic diseases, including type 2 diabetes and obesity. They were founded in 2010 with the goal of addressing the root causes of these conditions.

business area logo Core Business Areas

  • Revita DMR System: The Revita DMR System is Fractyl Health's primary product. It is a minimally invasive endoscopic procedure designed to remodel the duodenal lining to improve glucose control and reduce insulin resistance in patients with type 2 diabetes.
  • Preclinical Research: Fractyl Health continues to engage in preclinical research and development of new technologies and therapies related to metabolic disease.

leadership logo Leadership and Structure

Fractyl Health is led by a team of experienced medical device and biotechnology executives. Details on specific individuals and the complete organizational structure would require access to the company's investor relations materials and recent filings with the SEC. The company operates with standard biotech structure, and is lead by a Chief Executive Officer and department heads.

Top Products and Market Share

overview logo Key Offerings

  • Revita DMR System: The Revita DMR System is a minimally invasive endoscopic procedure that targets the duodenum. It is designed to regenerate the lining of the small intestine, aiming to improve insulin sensitivity and glucose control. Market share data specific to Revita DMR is difficult to obtain, as it is a relatively new and emerging technology. Revenue data requires private access. Competitors are largely other interventions for diabetes and obesity (medications, bariatric surgery).

Market Dynamics

industry overview logo Industry Overview

The market for diabetes and obesity treatments is large and growing, driven by the increasing prevalence of these conditions worldwide. The industry includes pharmaceutical companies, medical device manufacturers, and healthcare providers.

Positioning

Fractyl Health is positioned as an innovator in the treatment of type 2 diabetes and obesity, focusing on less invasive, durable therapies. Their competitive advantage lies in their unique approach to targeting the root causes of metabolic disease in the duodenum.

Total Addressable Market (TAM)

The TAM for type 2 diabetes and obesity treatments is estimated to be hundreds of billions of dollars globally. Fractyl Health is positioned to capture a portion of this market by providing a novel therapeutic option. A specific dollar amount would require further analysis of analyst reports.

Upturn SWOT Analysis

Strengths

  • Novel technology platform (Revita DMR)
  • Potential for durable glycemic control
  • Minimally invasive procedure
  • Strong intellectual property portfolio

Weaknesses

  • Limited clinical data compared to established therapies
  • Relatively new technology with an unproven long-term track record
  • Dependence on key personnel
  • Requires specialized training for physicians

Opportunities

  • Expansion of clinical indications
  • Partnerships with pharmaceutical companies and healthcare providers
  • Geographic expansion to new markets
  • Further development of technology platform

Threats

  • Competition from established diabetes and obesity treatments (medications, surgery)
  • Regulatory hurdles and reimbursement challenges
  • Adverse events associated with Revita DMR
  • Failure to demonstrate long-term efficacy

Competitors and Market Share

competitor logo Key Competitors

  • Novo Nordisk (NVO)
  • Eli Lilly and Company (LLY)
  • Medtronic (MDT)

Competitive Landscape

Fractyl Health faces significant competition from established pharmaceutical and medical device companies. Its success depends on demonstrating the safety, efficacy, and durability of Revita DMR compared to existing treatments.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is difficult to ascertain as a private company, but has likely focused on clinical trials and FDA approvals.

Future Projections: Future projections require access to company guidance or analyst models, which are not publicly available.

Recent Initiatives: Recent initiatives would center around continued clinical trials of Revita DMR and regulatory submissions.

Summary

Fractyl Health is an innovative private company working in the metabolic disease space. Their unique Revita DMR system offers promise, but faces hurdles of clinical validation, regulatory approval and commercial adoption. They compete in a market dominated by large players, making partnerships critical. Long-term success depends on positive clinical outcomes and strategic execution.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Press Releases
  • Analyst Reports (Limited Access)
  • SEC Filings of Competitors

Disclaimers:

This analysis is based on publicly available information and limited data. Financial data is estimated. Market share data is approximate and based on available industry reports and competitor filings. This is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Fractyl Health, Inc. Common Stock

Exchange NASDAQ
Headquaters Burlington, MA, United States
IPO Launch date 2024-02-02
Co-Founder, CEO & Director Dr. Harith Rajagopalan M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 103
Full time employees 103

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.